CN101735140A - 手性胺基化合物、合成方法及其抗流感药物达菲中间体的用途 - Google Patents
手性胺基化合物、合成方法及其抗流感药物达菲中间体的用途 Download PDFInfo
- Publication number
- CN101735140A CN101735140A CN200910200558A CN200910200558A CN101735140A CN 101735140 A CN101735140 A CN 101735140A CN 200910200558 A CN200910200558 A CN 200910200558A CN 200910200558 A CN200910200558 A CN 200910200558A CN 101735140 A CN101735140 A CN 101735140A
- Authority
- CN
- China
- Prior art keywords
- carbon
- amino compound
- group
- chiral amino
- catalyzer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 amino compound Chemical class 0.000 title claims abstract description 71
- 239000003814 drug Substances 0.000 title claims description 12
- 238000000034 method Methods 0.000 title abstract description 13
- 230000002194 synthesizing effect Effects 0.000 title abstract 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims abstract description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 42
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 42
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 claims description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- 229940061367 tamiflu Drugs 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- 230000000996 additive effect Effects 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000000377 silicon dioxide Substances 0.000 claims description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 5
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 5
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- 238000010189 synthetic method Methods 0.000 claims description 5
- 125000003368 amide group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 claims description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- CXDHJGCWMIOAQP-UHFFFAOYSA-N 2-pyridin-3-yl-1,4,5,6-tetrahydropyrimidine;hydrochloride Chemical compound Cl.C1CCNC(C=2C=NC=CC=2)=N1 CXDHJGCWMIOAQP-UHFFFAOYSA-N 0.000 claims description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 229960004249 sodium acetate Drugs 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 125000002769 thiazolinyl group Chemical group 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 16
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- 238000001819 mass spectrum Methods 0.000 description 16
- 238000004440 column chromatography Methods 0.000 description 15
- 239000003480 eluent Substances 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 230000005311 nuclear magnetism Effects 0.000 description 15
- 238000001228 spectrum Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000006555 catalytic reaction Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 239000000376 reactant Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000005576 amination reaction Methods 0.000 description 3
- 238000010523 cascade reaction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002081 enamines Chemical class 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 3
- 229960003752 oseltamivir Drugs 0.000 description 3
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- OKWJBGYZNFRKEC-UHFFFAOYSA-N benzenethiol toluene Chemical compound C1(=CC=CC=C1)S.CC1=CC=CC=C1 OKWJBGYZNFRKEC-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 150000007524 organic acids Chemical group 0.000 description 2
- 229960002194 oseltamivir phosphate Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 2
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005051 trimethylchlorosilane Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- UPLPHRJJTCUQAY-WIRWPRASSA-N 2,3-thioepoxy madol Chemical compound C([C@@H]1CC2)[C@@H]3S[C@@H]3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 UPLPHRJJTCUQAY-WIRWPRASSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- MPCRDALPQLDDFX-UHFFFAOYSA-L Magnesium perchlorate Chemical compound [Mg+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O MPCRDALPQLDDFX-UHFFFAOYSA-L 0.000 description 1
- 238000006683 Mannich reaction Methods 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 238000006957 Michael reaction Methods 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- BDKZHNJTLHOSDW-UHFFFAOYSA-N [Na].CC(O)=O Chemical compound [Na].CC(O)=O BDKZHNJTLHOSDW-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000006362 organocatalysis Methods 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 229940000673 orphan drug Drugs 0.000 description 1
- 239000002859 orphan drug Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- XZAFZXJXZHRNAQ-STQMWFEESA-N vosaroxin Chemical compound C1[C@H](OC)[C@@H](NC)CN1C1=CC=C2C(=O)C(C(O)=O)=CN(C=3SC=CN=3)C2=N1 XZAFZXJXZHRNAQ-STQMWFEESA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/02—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols
- C07C319/12—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols by reactions not involving the formation of mercapto groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/66—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
- C07C233/31—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/61—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
本发明方法涉及一种手性胺基化合物的合成方法及其用途,本发明提供的合成该化合物的方法简单,原料易得,操作简便,该化合物可以以更短路线合成达菲,适用于工业化生产,并且还可以合成一类多取代的手性四氢吡咯胺药物中间体。
Description
技术领域
本发明方法涉及一种手性胺基化合物、合成方法及其用途。
背景技术
学名Oseltamivir,中文名为奥司米韦(商品名为达菲),是GS-4071的乙酯型前药,可以阻断流感病毒NA对病毒感染细胞表面的唾液酸残基的裂解,从而抑制新生病毒粒从宿主细胞的释放。Oseltamivir具有很高的口服活性,并经过体内肝酯酶的代谢生成活性的GS-4071,而产生抑制流感病毒NA的疗效。
R=H,GS-4071,IC50=1nM;
R=CH2CH3,GS-4104,Tamiflu
Oseltamivir由Roche公司研发生产并于1999年在瑞士上市,其片剂是第一个口服方便的流感病毒NA抑制剂,用于治疗A型和B型流感,并可减少1-12岁患者并发中耳炎。2000年,Tamiflu的磷酸盐(Oseltamivir phosphate,GS-4101/002)被美国FDA批准上市用于13岁以上的人群预防A型和B型流感。同时Tamiflu的耐受性很好,没有严重副作用的报道。
Tamiflu的合成路线主要有以下几条:
目前工业上使用最为成熟的是Roche公司开发的以莽草酸((-)-shikimic acid)为起始原料的路线(J.Am.Chem.Soc.,1997,119,681)。
2006年Corey提出的合成路线,12步总收率27%(J.Am.Chem.Soc.,2006,128,6310)。
2008年Trost提出的合成路线,8步总收率30%(Angew.Chem.Int.Ed.2008,47,3759)。
2009年Hayashi提出的合成路线,总收率57%(Angew.Chem.Int.Ed.2009,48,1304)。
最近几年由于H5N1型病毒引起的禽流感肆虐,使得Tamiflu的需求量越来越大。人们期望能开发出更为经济,操作简便的新合成路线,以便于更加效率的合成达菲。
多取代的手性四氢吡咯胺中间体在多种药物或活性分子中广泛存在,例如:
总结目前合成多取代的手性四氢吡咯胺的方法都具有步骤冗长,产率不高,选择性不好,操作复杂,成本过高等缺点,因此人们急需开发出一种经济简便的合成多取代的手性四氢吡咯胺的方法。
不对称催化为化学家提供了新的有力的工具高效合成复杂的分子。本世纪初,在Barbas,List,MacMillan等人的努力之下,有机催化(organocatalysis)得到了蓬勃的发展,迅速成为不对称催化的新领域(Angew.Chem.Int.Ed.2001,40,3726)。
有机催化是连接金属有机催化和酶催化以及合成化学和生物有机化学的桥梁。得益于催化剂来源广泛,易制备,价格便宜;易操作,一般不需要无水无氧;避免了有毒的金属残留等优点,有机催化引起了化学界和工业界的极大兴趣,权威杂志的连续评述,已成为当前的热门课题。
不对称催化的对映选择性的Michael加成反应一直以来被认为是最有力而可靠的形成C-C键和C-杂键的方法,大量的实例被应用在全合成当中。因为如此,最近几年里,大量的有机催化的Michael反应见诸报道,包含各种亲核试剂和Michael受体(Synthesis 2007,14,2065-2092)。同时,将Michael反应用在Domino反应或是One-pot反应中用以高效构建多手性中心的复杂分子也已成为当前的热门研究领域。
最近手性胺与羰基化合物形成烯胺或亚胺活化的过渡态的不对称研究取得了显著的进展。化学家们最重要的一个目标就是设计一个底物普适性较强的催化剂,这通常需要耗费极大的工作量从事单调的催化剂筛选工作,因为只有少数催化剂较为优秀。其中,Jorgensen和Hayashi发现的Diarylprolinol Ethers最近得到了重视,并已经成功地应用于醛的α-官能团化C-X键的形成,大量的转化如C-X(X=F,Br,S)键形成、α-胺化、Mannich反应等等。
2006年Enders在Nature上发表了有机催化的三组分串联反应(Nature 2006,441,861),通过催化的烯胺、亚胺、烯胺这几个物种的Michael/Michael/Adol串联反应的过程一步构建了一个带有四个手性中心,多个的官能团的六元环。
发明内容
本发明的目的是提供一种手性胺基化合物,可用作达菲的关键中间体、手性四氢吡咯胺药物中间体;
本发明的目的还提供一种上述化合物的合成方法,该方法原料易得,操作简便适用于工业化生产。
本发明的另一目的是提供上述化合物的用途,即可以更加简便经济地合成达菲药物,和合成一类多取代的手性四氢吡咯胺药物中间体。
本发明提供的手性胺基化合物具有如下的结构式:
其中R1为1~10个碳的烷基,1~10个碳的烷氧基,R4取代的1~4个碳的烷基,5~12个碳的芳香基,吸电子基或给电子基单取代或多取代的5~12个碳的芳香基。进一步推荐R1为1~4个碳的烷基,1~4个碳的烷氧基,R4取代的1~4个碳的烷基,苯基,吸电子基或给电子基单取代、二取代或三取代的苯基;
所述的R4为氨基、取代的胺基、羟基、取代的羟基、2~10个碳的酯基或2~6个碳的烯基;所述的取代的胺基上的取代基为叔丁氧羰基、苄氧羰基、苄基、乙酰基、三氟甲基羰基或邻苯二甲酰基();所述的取代的羟基上的取代基为苄基、乙酰基、甲氧甲基、二甲基叔丁基硅基、三甲基硅基、三乙基硅基、二苯基叔丁基硅基或2-四氢吡喃基;
所述的吸电子基推荐卤素、腈基或硝基,所述的卤素例如F、Cl、Br或I,所述的给电子基推荐1~4个碳的烷基、1~4个碳的烷氧基、胺基或羟基。其中R2、R3为氮的保护基或氢,所述的氮的保护基为叔丁氧羰基、苄氧羰基、苄基、乙酰基、三氟甲基羰基、或其它酰基类保护基。
本发明的手性胺基化合物推荐具有如下的结构式或其对映体:
其中,Boc=叔丁氧羰基;Bn=苄基;Ac=乙酰基;Phth=邻苯二甲酰基;Cbz代表苄氧羰基。
其中R1、R2和R3如前所述。
本发明的合成上述手性胺基化合物的方法可以进一步描述为:
在-20~30℃条件下,如上的醛与硝基烯在催化剂,添加剂存在下,在一定溶剂中经过10min~48h反应。反应推荐在-20℃~30℃条件下进行,所述的添加剂是有机酸或弱碱盐。
其中催化剂具有如下结构式:
如前所述;如二叔丁基甲基硅基、三甲基硅基、H或其组合;所述的添加剂推荐有机酸或弱碱盐中的醋酸、苯甲酸、醋酸钠、氯乙酸或其组合;所述的溶剂推荐水、二氯甲烷、1,2-二氯乙烷、乙腈、四氢呋喃、甲醇、乙醇、甲苯、N,N-二甲基甲酰胺、乙二醇二甲醚、二甲基亚砜或其组合;
所述的醛、硝基烯、催化剂和添加剂的摩尔比推荐1.0-4.0∶1.0-2.0∶0.01-0.20和0-0.50。
本发明的手性胺基化合物可以用来合成达菲,合成路线简便经济,具体路线如下所示:
上述路线中,条件是:a.2-二乙氧基氧磷丙烯酸乙酯,碳酸铯,0℃1小时,乙醇,室温;b.对甲基苯硫酚;c.锌粉,三甲基氯硅烷,乙醇;d.氨气,碳酸钾,乙醇,室温。
本发明的手性胺基化合物还可以合成一类手性四氢吡咯胺药物中间体,这类中间体是多取代的手性四氢吡咯胺,推荐二取代的手性四氢吡咯胺,具体路线如下所示:
上述路线中,条件推荐:
条件1在极性溶剂中和催化剂的作用下,0℃-100℃以及(1-100)×105Pa压力下与氢气反应,反应物与催化剂的重量比为1∶0.001-0.2,所述的催化剂是Pd/C,Pd(OH)2/C,PtO2,Ranny-Ni;
条件2Zn/HOAc,Fe粉,Ranny-Ni/H2还原反应物中硝基,之后发生还原氨化反应得到产物。还原氨化反应在溶剂中并在催化剂存在下进行,其中所述溶剂包括二氯甲烷,四氢呋喃或1,2-二氯甲烷或其组合,所述催化剂包括硼氢化钠,氰基硼氢化钠,醋酸硼氢化钠,硼烷/吡啶,硼氢化钠/高氯酸镁,硼氢化锌/氯化锌,三乙酰氧基硼氢化钠。
合成方法参见Drugs of the Future 2009,34,363。
综上所述,本发明提供了一种合成手性胺基化合物的方法,本发明提供了该中间体合成达菲的方法,原料易得,操作简便,路线短,适用于工业化生产,并提供了该中间体合成一类多取代的手性四氢吡咯胺药物中间体。
具体实施方式
以下实例有助于了解本发明,但不局限于本发明的内容。
5mL蛋形瓶中,依次加入催化剂(5mol%),硝基烯(1mmol),醋酸(5倍催化剂当量),加入2mL乙腈和搅拌子,0℃下加入醛(1.5mmol)。,TLC跟踪硝基烯至原料消失。旋干,柱层析(淋洗剂:石油醚/乙酸乙酯=5∶1)得产品。产率:98%。非对映异构体的比例通过粗产品氢谱核磁来确定,dr:11:1,光学纯度值通过手性HPLC柱来确定,ee:98%。核磁分析:1H NMR(400MHz,CDCl3)δ9.72(s,1H),7.87-7.85(m,2H),7.78-7.76(m,2H),5.24(dt,1H,J=3.2,10.4Hz),5.17(dd,1H,J=2.8,12.8Hz),4.85(dd,1H,2.8,12.8Hz),3.37-3.29(m,1H),1.15(d,3H,J=7.6Hz);质谱:MS(m/z)276.2(M+);比旋光:[α]D 22=-104.8(c=1.00 in CHCl3).
5mL蛋形瓶中,依次加入催化剂(5mol%),硝基烯(1mmol),醋酸(5倍催化剂当量),加入2mL乙腈和搅拌子,0℃下加入醛(1.5mmol)。1小时后自然升至室温,TLC跟踪硝基烯至原料消失。旋干,柱层析(淋洗剂:石油醚/乙酸乙酯=5∶1)得产品。产率:98%。非对映异构体的比例通过粗产品氢谱核磁来确定,dr:15:1,,光学纯度值通过手性HPLC柱来确定,ee:99%。核磁分析:1H NMR(400MHz,CDCl3)δ9.76(d,1H,J=0.8Hz),7.89-7.87(m,2H),7.81-7.76(m,2H),5.32(dt,1H,J=3.6,10.8Hz),5.13(dd,1H,J=10.4,13.2Hz),4.82(dd,1H,J=3.2,12.8Hz),3.41-3.36(m,1H),1.87-1.80(m,1H),1.64-1.57(m,1H),0.90(t,3H,J=7.6Hz);质谱:MS(m/z)290.2(M+);比旋光:[α]D 22=-73.2(c=1.13 in CHCl3).
5mL蛋形瓶中,依次加入催化剂(5mol%),硝基烯(1mmol),醋酸(5倍催化剂当量),加入2mL乙腈和搅拌子,0℃下加入醛(1.5mmol)。1小时后自然升至室温,TLC跟踪硝基烯至原料消失。旋干,柱层析(淋洗剂:石油醚/乙酸乙酯=5∶1)得产品。Syn/anti比通过粗产品核磁确定,ee值通过手性HPLC来确定。非对映异构体的比例通过粗产品氢谱核磁来确定,dr:9:1,光学纯度值通过手性HPLC柱来确定,ee:99%。核磁分析:1H NMR(400MHz,CDCl3)δ9.74(s,1H),7.84-7.82(m,2H),7.74-7.72(m,2H),7.34-7.26(m,1H),7.25-7.22(m,2H),7.16-7.14(m,2H),5.31(dt,1H,J=3.2,10.4Hz),5.14(dd,1H,J=10.4,12.8Hz),4.78(dd,1H,J=3.2,13.2Hz),4.32(s,2H),3.42-3.38(m,1H),3.35(t,2H,J=5.6Hz),1.88-1.80(m,1H),1.74-1.61(m,1H),1.52-1.43(m,2H);质谱:MS(m/z)410.4(M+);比旋光:[α]D 22=-45.89(c=1.26 in CHCl3).
实施例4的合成
5mL蛋形瓶中,依次加入催化剂(10mol%),硝基烯(1mmol),醋酸(5倍催化剂当量),加入2mL乙腈和搅拌子,0℃下加入醛(1.5mmol)。1小时后自然升至室温,TLC跟踪硝基烯至原料消失。旋干,柱层析(淋洗剂:石油醚/乙酸乙酯=5∶1)得产品。产率:98%。非对映异构体的比例通过粗产品氢谱核磁来确定,dr:8:1,光学纯度值通过手性HPLC柱来确定,ee:>99%。核磁分析:1H NMR(400MHz,CDCl3)δ9.83(s,1H),7.88-7.85(m,2H),7.80-7.78(m,2H),5.43-5.34(m,1H),5.23(dd,1H,J=10.4,13.6Hz),4.93(dd,1H,J=3.2,13.6Hz),4.85(t,1H,J=11.2Hz),3.96-3.89(m,1H),3.49-3.41(m,1H),3.16-3.10(m,1H),1.40(s,9H);质谱:MS(m/z)391.3(M+);比旋光:[α]D 22=-75.4(c=1.00in CHCl3).
5mL蛋形瓶中,依次加入催化剂(10mol%),硝基烯(1mmol),醋酸(5倍催化剂当量),加入2mL乙腈和搅拌子,0℃下加入醛(1.5mmol)。1小时后自然升至室温,TLC跟踪硝基烯至原料消失。旋干,柱层析(淋洗剂:石油醚/乙酸乙酯=5∶1)得产品。Syn/anti比通过粗产品核磁确定,ee值通过手性HPLC来确定。非对映异构体的比例通过粗产品氢谱核磁来确定,dr:7:1,光学纯度值通过手性HPLC柱来确定,ee:96%。核磁分析:1H NMR(400MHz,CDCl3)δ9.84(s,1H),7.89-7.86(m,2H),7.79-7.77(m,2H),5.41-5.36(m,2H),4.97(dd,1H,J=3.2,13.2Hz),4.04(q,2H,J=7.2Hz),3.58-3.52(m,1H),2.71-2.68(m,2H),1.18-1.14(t,3H,J=14.7Hz);质谱:MS(m/z)348.3(M+);比旋光:[α]D 22=-43.1(c=1.00 in CHCl3).
5mL蛋形瓶中,依次加入催化剂(10mol%),硝基烯(1mmol),醋酸(5倍催化剂当量),加入2mL乙腈和搅拌子,0℃下加入醛(1.5mmol)。1小时后自然升至室温,TLC跟踪硝基烯至原料消失。旋干,柱层析(淋洗剂:石油醚/乙酸乙酯=5∶1)得产品。非对映异构体的比例通过粗产品氢谱核磁来确定,dr:11:1,ee值通过手性HPLC来确定,ee:98%。核磁分析:1H NMR(400MHz,CDCl3)δ9.67(S,1H,),8.03-8.01(m,2H),7.94-7.92(m,2H),5.56(dt,1H,J=3.6,10.8Hz),5.38(dd,1H,J=10.8,13.2Hz),5.01(dd,1H,J=3.2,13.2Hz),4.91(d,1H,J=10.0Hz),4.44(q,1H,J=10.4Hz),1.82(d,3H,J=27.2Hz);质谱:MS(m/z)316.3(M+);比旋光:[α]D 22=-83.1(c=1.00 in CHCl3)
5mL蛋形瓶中,依次加入催化剂(10mol%),硝基烯(1mmol),醋酸(5倍催化剂当量),加入2mL乙腈和搅拌子,0℃下加入醛(1.5mmol)。1小时后自然升至室温,TLC跟踪硝基烯至原料消失。旋干,柱层析(淋洗剂:石油醚/乙酸乙酯=5∶1)得产品。非对映异构体的比例通过粗产品氢谱核磁来确定,dr:12:1,ee值通过手性HPLC来确定,ee:98%。核磁分析:1H NMR(400MHz,CDCl3)δ9.70(s,1H),7.70-7.63(m,4H),7.24-7.14(m,5H),5.71(dt,1H,J=3.2,10.8Hz),5.25(dd,1H,J=10.8,13.2Hz),4.95(dd,1H,J=3.2,12.8Hz),4.60(d,1H,J=11.6Hz);质谱:MS(m/z)338.3(M+);比旋光:[α]D 22=-65.2(c=1.00in CHCl3)。
5mL蛋形瓶中,依次加入催化剂(10mol%),硝基烯(1mmol),醋酸(5倍催化剂当量),加入2mL乙腈和搅拌子,0℃下加入醛(1.5mmol)。1小时后自然升至室温,TLC跟踪硝基烯至原料消失。旋干,柱层析(淋洗剂:石油醚/乙酸乙酯=5∶1)得产品。非对映异构体的比例通过粗产品氢谱核磁来确定,dr:14:1,ee值通过手性HPLC来确定,ee:95%。核磁分析:1H NMR(400MHz,CDCl3)δ9.66(s,1H),7.72-7.66(m,4H),7.23(d,2H,J=8.4Hz),7.11(d,2H,J=2.1Hz),5.68(dt,1H,J=3.2,10.8Hz),5.22(dd,1H,J=10.4,13.2Hz),4.93(dd,1H,J=3.2,13.6Hz),4.62(d,1H,J=11.2Hz);质谱:MS(m/z)372.7(M+);比旋光:[α]D 22=-55.2(c=1.00 in CHCl3)。
5mL蛋形瓶中,依次加入催化剂(10mol%),硝基烯(1mmol),醋酸(5倍催化剂当量),加入2mL乙腈和搅拌子,0℃下加入醛(1.5mmol)。1小时后自然升至室温,TLC跟踪硝基烯至原料消失。旋干,柱层析(淋洗剂:石油醚/乙酸乙酯=5∶1)得产品。非对映异构体的比例通过粗产品氢谱核磁来确定,dr:15:1,ee值通过手性HPLC来确定,ee:96%。核磁分析:1H NMR(400MHz,CDCl3)δ9.65(s,1H),7.75-7.73(m,2H),7.02-7.66(m,2H),7.35(d,1H,J=8Hz),7.30(d,1H,J=2Hz),7.02(dd,1H,J=2,8Hz),5.67(dt,1H,J=3.6,10.8Hz),5.20(dd,1H,J=10.4,12.8Hz),4.90(dd,1H,J=3.2,13.2Hz);质谱:MS(m/z)407.2(M+);比旋光:[α]D 22=-78.1(c=1.00 in CHCl3)。
5mL蛋形瓶中,依次加入催化剂(10mol%),硝基烯(1mmol),醋酸(5倍催化剂当量),加入2mL乙腈和搅拌子,0℃下加入醛(1.5mmol)。1小时后自然升至室温,TLC跟踪硝基烯至原料消失。旋干,柱层析(淋洗剂:石油醚/乙酸乙酯=5∶1)得产品。非对映异构体的比例通过粗产品氢谱核磁来确定,dr:15:1,,ee值通过手性HPLC来确定,ee:95%。核磁分析:1H NMR(400MHz,CDCl3)δ9.68(s,1H),7.71-7.64(m,4H),7.15(dd,2H,J=5.2,8.8Hz),6.94(t,2H,J=8.4Hz),5.67(dt,1H,J=3.2,10.8Hz),5.23(dd,1H,J=10.8,13.2Hz),4.60(d,1H,J=11.2Hz);质谱:MS(m/z)356.3(M+);比旋光:[α]D 22=-95.2(c=1.00in CHCl3)。
5mL蛋形瓶中,依次加入催化剂(5mol%),硝基烯(1mmol),醋酸(5倍催化剂当量),加入2mL乙腈和搅拌子,0℃下加入醛(1.5mmol)。1小时后自然升至室温,TLC跟踪硝基烯至原料消失。旋干,柱层析(淋洗剂:石油醚/乙酸乙酯=5∶1)得产品。非对映异构体的比例通过粗产品氢谱核磁来确定,dr:5:1,,ee值通过手性HPLC来确定,ee:95%。核磁分析:1H NMR(400MHz,CDCl3)δ9.68(s,1H),7.71-7.64(m,4H),7.15(dd,2H,J=5.2,8.8Hz),6.94(t,2H,J=8.4Hz),5.67(dt,1H,J=3.2,10.8Hz),5.23(dd,1H,J=10.8,13.2Hz),4.60(d,1H,J=11.2Hz);质谱:MS(m/z)292.1(M+);比旋光:[α]D 22=-95.2(c=1.00in CHCl3)。
实施例12的合成
5mL蛋形瓶中,依次加入催化剂(10mol%),硝基烯(1mmol),苯甲酸(3倍催化剂当量),加入2mL氯仿和搅拌子,0℃下加入醛(2mmol)。1小时后自然升至室温,TLC跟踪硝基烯至原料消失。旋干,柱层析(淋洗剂:石油醚/乙酸乙酯=1∶1)得产品。非对映异构体的比例通过粗产品氢谱核磁来确定,dr:5:1,ee值通过手性HPLC来确定,ee:96%。核磁分析:1H NMR(400MHz,CDCl3)δ9.73(s,1H),6.20(d,1H,J=8.4Hz),5.09-5.02(m,1H),4.58(d,2H,J=6.8Hz),4.08(d,1H,J=3.2Hz),3.42-3.37(m,1H),1.98(s,3H),1.61-1.35(m,4H),0.95-0.83(m,6H);质谱:MS(m/z)260.2(M+);比旋光:[α]D 22=-2.2(c=1.00in CHCl3).
实施例13
将反应物(1mmol)溶于二氯甲烷中,室温下加入2-二乙氧基氧磷丙烯酸乙酯(1mmol),碳酸铯(3mmol),1小时后减压蒸除溶剂,加入3ml乙醇,-15℃加入对甲基苯硫酚(4mmol)反应12h;1N盐酸溶液淬灭反应,氯仿萃取三次,饱和氯化钠洗涤有机相,无水硫酸镁干燥,减压蒸除溶剂,柱层析(淋洗剂:石油醚/乙酸乙酯=2∶1)得产品。非对映异构体的比例通过粗产品氢谱核磁来确定,光学纯度值通过手性HPLC柱来确定ee:96.40%。核磁分析:1H NMR(400MHz,CDCl3)δ7.38(d,2H,J=8Hz),7.07(d,2H,J=8Hz),5.88(d,1H,J=6Hz),5.56-5.48(m,1H),4.44(dd,1H,J=3.6,10.4Hz),4.13-4.09(m,1H),4.07-4.06(m,1H),3.95-3.84(m,2H),3.21-3.16(m,1H),2.88(dt,1H,J=13.2,3.2Hz),2.57-2.53(m,1H),2.37(q,1H,J=13.2Hz),2.31(s,3H),1.94(s,3H),1.50-1.41(m,1H),1.39-1.33(m,1H)1.18(t,3H,J=7.2Hz),1.13-1.07(m,2H),0.81(t,3H,J=7.2Hz),0.61(t,3H,J=7.6Hz);MS(m/z)466.5(M+);比旋光:[α]D 22=-47.65(c=0.62 in CHCl3).
实施例14
将反应物溶于乙醇(1mmol),室温氩气保护下,加入锌粉(50mmol),三甲基氯硅烷(30mmol),70℃反应4小时,-20℃通入氨气5分钟,恢复室温加入碳酸钾(20mmol)反应6小时,减压蒸除溶剂,溶于1N盐酸溶液,乙酸乙酯洗涤,氨水调pH值为12,氯仿萃取3次,饱和氯化钠洗涤有机相,无水硫酸镁干燥,减压蒸除溶剂得产品。产率:92%。核磁分析:1H NMR(400MHz,CDCl3)δ6.78(t,J=2.0Hz,1H),5.62(d,J=7.6Hz,1H),4.20(q,J=7.2Hz,2H),4.15-4.20(m,1H),3.52(q,J=8.0Hz,1H),3.34(quintet,J=5.6Hz,1H),3.24(dt,J=5.2,10.0Hz,1H),2.75(dd,J=17.6,5.2Hz,1H),2.15(ddt,J=17.6,10.0,2.8Hz,1H),2.04(s,3H),1.40-1.60(m,4H),1.29(t,J=7.2Hz,3H),0.90(t,J=7.2Hz,3H),0.89(t,J=7.2Hz,3H);质谱:MS(m/z)312.4(M+);比旋光:[α]D 22=-54.9(c 1.40,CHCl3).
实施例15
将反应物(1mmol)溶于10ml乙醇,加入反应物重量10%的Pd(OH)2/C,在室温5个大气压下与氢气反应48h,减压蒸除溶剂,柱层析(淋洗剂:二氯甲烷/甲醇=10∶1)得产品。核磁分析:1H NMR(400MHz,CDCl3)δ7.86-7.83(m,2H),7.74-7.71(m,2H),3.63-3.54(m,2H),3.39-3.30(m,1H),2.87-2.82(m,1H),2.75(br,1H),1.26(m,1H)1.17(d,J=6.4Hz,3H);质谱:MS(m/z)230.1(M+)
实施例16
将反应物(1mmol)溶于醋酸和10ml水,0℃加入Zn粉,反应10分钟后,NaOH固体调pH值碱性,乙酸乙酯萃取三次,饱和氯化钠洗涤有机相,无水硫酸镁干燥,减压蒸除溶剂,加入10ml甲醇,0℃分批加入NaBH4(1.2mmol)24小时后减压蒸除溶剂,柱层析(淋洗剂:二氯甲烷/甲醇=10∶1)得产品。核磁分析:1H NMR(400MHz,CDCl3)δ7.87-7.83(m,2H),7.74-7.71(m,2H),4.63(m,1H),3.62(t,J=8.4Hz,1H),3.51-3.46(m,1H),3.35(m,1H),2.89(t,J=8.4Hz,1H),2.58(m,1H),1.64-1.50(m,2H),1.26(m,1H),0.89(t,J=7.2Hz,3H);质谱:MS(m/z)244.2(M+)。
实施例17
将反应物(1mmol)溶于6ml乙腈,依次加入RCl(4mmol),DBU(5mmol),70-75℃下加热2小时,冷去后过滤得固体,10ml乙醇,加入水合肼(100mg,2mmol),回流过夜,冷却柱层析,加入2N NaOH皂化后得产品。核磁分析:1H NMR(300MHz,CDCl3)δ8.61(s,1H),7.05(brs,2H),4.08-4.20(m,1H),3.75-3.89(m,1H),3.60(d,J=10.0Hz,1H),3.42(d,J=10.0Hz,1H),3.01-3.32(m,2H),2.35(m,3H),1.04-1.20(m,2H),0.38-0.90(m,6H);质谱:MS(m/z)389.2(M+H+)。
Claims (6)
1.一种手性胺基化合物,其特征是具有如下结构式:
其中,R1为1~10个碳的烷基,1~10个碳的烷氧基,R4取代的1~4个碳的烷基,5~12个碳的芳香基,吸电子基或给电子基单取代或多取代的5~12个碳的芳香基;
所述的取代的羟基上的取代基为苄基、乙酰基、甲氧甲基、二甲基叔丁基硅基、三甲基硅基、三乙基硅基、二苯基叔丁基硅基或2-四氢吡喃基;
2.如权利要求1所述的手性胺基化合物,其特征是所述的吸电子基是卤素、腈基或硝基,所述的给电子基是1~4个碳的烷基、1~4个碳的烷氧基、羟基或胺基。
5.如权利要求4所述的手性胺基化合物的合成方法,其特征是所述的溶剂是水、二氯甲烷、1,2-二氯乙烷、氯仿、乙腈、四氢呋喃、甲醇、乙醇、甲苯、N,N-二甲基甲酰胺、乙二醇二甲醚、二甲基亚砜或其组合;
6.一种如权利要求1所述的手性胺基化合物用于制备达菲或手性四氢吡咯胺药物中间体。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910200558A CN101735140A (zh) | 2009-12-23 | 2009-12-23 | 手性胺基化合物、合成方法及其抗流感药物达菲中间体的用途 |
PCT/CN2010/079936 WO2011076086A1 (zh) | 2009-12-23 | 2010-12-17 | 达菲的中间体化合物及其合成方法和用途 |
US14/123,870 US9040738B2 (en) | 2009-12-23 | 2010-12-17 | Intermediate compounds of tamiflu, methods of preparation and uses thereof |
CN2010106132468A CN102127003B (zh) | 2009-12-23 | 2010-12-17 | 抗流感药物达菲的中间体化合物及其合成方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910200558A CN101735140A (zh) | 2009-12-23 | 2009-12-23 | 手性胺基化合物、合成方法及其抗流感药物达菲中间体的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101735140A true CN101735140A (zh) | 2010-06-16 |
Family
ID=42459222
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910200558A Pending CN101735140A (zh) | 2009-12-23 | 2009-12-23 | 手性胺基化合物、合成方法及其抗流感药物达菲中间体的用途 |
CN2010106132468A Active CN102127003B (zh) | 2009-12-23 | 2010-12-17 | 抗流感药物达菲的中间体化合物及其合成方法和用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010106132468A Active CN102127003B (zh) | 2009-12-23 | 2010-12-17 | 抗流感药物达菲的中间体化合物及其合成方法和用途 |
Country Status (3)
Country | Link |
---|---|
US (1) | US9040738B2 (zh) |
CN (2) | CN101735140A (zh) |
WO (1) | WO2011076086A1 (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011076086A1 (zh) * | 2009-12-23 | 2011-06-30 | 中国科学院上海有机化学研究所 | 达菲的中间体化合物及其合成方法和用途 |
CN102180821A (zh) * | 2011-03-10 | 2011-09-14 | 杭州师范大学 | 一种达菲中间体及其合成方法 |
EP2385034A3 (en) * | 2010-05-05 | 2012-07-18 | Synkola, s.r.o. | Process for the preparation of 1-nitro-4-oxobutanylamides |
US8980829B2 (en) | 2011-02-18 | 2015-03-17 | Shanghai Yingli Science And Technology Co., Ltd | Aryl glycoside compound, preparation method and use thereof |
CN105330558A (zh) * | 2011-03-08 | 2016-02-17 | 公益财团法人微生物化学研究会 | 化合物及其生产方法,以及用于生产磷酸奥司他韦的方法 |
CN107121506A (zh) * | 2017-04-13 | 2017-09-01 | 杭州华东医药集团新药研究院有限公司 | 奥泽沙星杂质及其用途 |
CN107304171A (zh) * | 2017-05-05 | 2017-10-31 | 杭州师范大学 | 一种奥司他韦的合成方法 |
CN111018901A (zh) * | 2013-09-09 | 2020-04-17 | 中国科学院上海有机化学研究所 | 扎那米韦和拉那米韦的中间体及其合成方法 |
CN111763157A (zh) * | 2020-04-26 | 2020-10-13 | 中山大学 | 一种手性氨基化合物及其制备方法和应用、及由其制备依度沙班中间体的制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114634471B (zh) * | 2022-04-14 | 2023-05-19 | 河南师范大学 | 一种合成γ-羟基-γ-全氟甲基环外双键丁内酯类化合物的方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080009639A1 (en) | 2006-07-10 | 2008-01-10 | Apotex Pharmachem Inc. | Preparation of oseltamivir phosphate (Tamiflu) and intermediates starting from D-glucose or D-xylose |
WO2009078813A1 (en) | 2007-12-19 | 2009-06-25 | Nanyang Technological University | Method of forming oseltamivir and derivatives thereof |
CN103288696B (zh) * | 2008-05-30 | 2015-08-19 | 住友化学株式会社 | 磷酸奥司他韦的中间体化合物 |
CN101735140A (zh) | 2009-12-23 | 2010-06-16 | 中国科学院上海有机化学研究所 | 手性胺基化合物、合成方法及其抗流感药物达菲中间体的用途 |
-
2009
- 2009-12-23 CN CN200910200558A patent/CN101735140A/zh active Pending
-
2010
- 2010-12-17 CN CN2010106132468A patent/CN102127003B/zh active Active
- 2010-12-17 WO PCT/CN2010/079936 patent/WO2011076086A1/zh active Application Filing
- 2010-12-17 US US14/123,870 patent/US9040738B2/en not_active Expired - Fee Related
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011076086A1 (zh) * | 2009-12-23 | 2011-06-30 | 中国科学院上海有机化学研究所 | 达菲的中间体化合物及其合成方法和用途 |
US9040738B2 (en) | 2009-12-23 | 2015-05-26 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Intermediate compounds of tamiflu, methods of preparation and uses thereof |
EP2385034A3 (en) * | 2010-05-05 | 2012-07-18 | Synkola, s.r.o. | Process for the preparation of 1-nitro-4-oxobutanylamides |
US8980829B2 (en) | 2011-02-18 | 2015-03-17 | Shanghai Yingli Science And Technology Co., Ltd | Aryl glycoside compound, preparation method and use thereof |
CN105330558A (zh) * | 2011-03-08 | 2016-02-17 | 公益财团法人微生物化学研究会 | 化合物及其生产方法,以及用于生产磷酸奥司他韦的方法 |
CN102180821A (zh) * | 2011-03-10 | 2011-09-14 | 杭州师范大学 | 一种达菲中间体及其合成方法 |
CN111018901A (zh) * | 2013-09-09 | 2020-04-17 | 中国科学院上海有机化学研究所 | 扎那米韦和拉那米韦的中间体及其合成方法 |
CN111018901B (zh) * | 2013-09-09 | 2021-09-03 | 中国科学院上海有机化学研究所 | 扎那米韦和拉那米韦的中间体及其合成方法 |
CN107121506A (zh) * | 2017-04-13 | 2017-09-01 | 杭州华东医药集团新药研究院有限公司 | 奥泽沙星杂质及其用途 |
CN107121506B (zh) * | 2017-04-13 | 2019-06-07 | 杭州华东医药集团新药研究院有限公司 | 奥泽沙星杂质及其用途 |
CN107304171A (zh) * | 2017-05-05 | 2017-10-31 | 杭州师范大学 | 一种奥司他韦的合成方法 |
CN111763157A (zh) * | 2020-04-26 | 2020-10-13 | 中山大学 | 一种手性氨基化合物及其制备方法和应用、及由其制备依度沙班中间体的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US20140221662A1 (en) | 2014-08-07 |
US9040738B2 (en) | 2015-05-26 |
CN102127003A (zh) | 2011-07-20 |
CN102127003B (zh) | 2013-09-11 |
WO2011076086A1 (zh) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101735140A (zh) | 手性胺基化合物、合成方法及其抗流感药物达菲中间体的用途 | |
CN106083837B (zh) | 一种噁唑烷酮类抗菌药物及其中间体的制备方法 | |
US6372920B1 (en) | Process for preparing nitrogen-substituted aminotetralins | |
CN102584795B (zh) | 一种克里唑替尼的制备方法 | |
CN115181066B (zh) | 一种6-氯-2-甲基-2h-吲唑-5-胺的合成方法 | |
EP4186915A1 (en) | Method for synthesizing c-nucleoside compound | |
CN112062767A (zh) | 一种卢美哌隆的制备方法及其中间体 | |
CN101817773A (zh) | 手性α-非天然氨基酸的制备方法 | |
Swift et al. | Studies on the aza-Claisen rearrangement of 4, 5-dihydroxylated allylic trichloroacetimidates: the stereoselective synthesis of (2R, 3S)-and (2S, 3S)-2-amino-3, 4-dihydroxybutyric acids | |
CN103111323B (zh) | 手性n,n-二烷基-1,2-环己二胺催化剂及其制备方法和应用 | |
TWI540119B (zh) | 化合物、及其製造方法、以及磷酸奧司他韋之製造方法 | |
CN101333175A (zh) | 制备d-天冬酰胺及d-高丝氨酸的方法 | |
CN106111190A (zh) | 一种手性联芳骨架吡哆胺类催化剂及其合成方法与应用 | |
CN102250005B (zh) | 艾利西平的制备方法 | |
CN101628889B (zh) | 一种改进的盐酸多奈哌齐关键中间体的制备方法 | |
CN109320510B (zh) | 一种马罗匹坦游离碱的制备方法 | |
CN114621287A (zh) | 一种氘代瑞德西韦化合物、其合成方法及用途 | |
CN110256441A (zh) | 一种巴瑞克替尼的制备方法 | |
CN115160162B (zh) | 一种α氨基β酮酸酯的不对称氢化方法 | |
CN103755624B (zh) | 一种哌啶衍生物的合成方法 | |
WO2004103990A1 (ja) | 光学活性n-モノアルキル-3-ヒドロキシ-3-アリールプロピルアミン類の製造方法および中間体 | |
CN117142934A (zh) | 一种(s)-3-环己烯-1-甲酸及其中间体的制备方法 | |
CN115785102A (zh) | 一种碘代吲哚喹唑啉胺类化合物的合成方法 | |
CN111892627A (zh) | α-氨基磷氧化物的绿色合成方法 | |
CN117004663A (zh) | 合成(r)-4-丙基二氢呋喃-2(3氢)-酮的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100616 |